Cargando…

Intelligent tunable CAR-T cell therapy leads the new trend

Adoptive transfer of T cells engineered with chimeric antigen receptor (CAR) has been proved to have robust anti-tumor effects against hematological malignancies. However, problems about safety and efficacy, such as cytokine release syndrome (CRS), T cell exhaustion and antigen escape are still rais...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Jiayi, Liu, Mingyao, Zhang, Jiqin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: KeAi Publishing 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518343/
https://www.ncbi.nlm.nih.gov/pubmed/37753197
http://dx.doi.org/10.1016/j.synbio.2023.09.001
_version_ 1785109492858355712
author Cheng, Jiayi
Liu, Mingyao
Zhang, Jiqin
author_facet Cheng, Jiayi
Liu, Mingyao
Zhang, Jiqin
author_sort Cheng, Jiayi
collection PubMed
description Adoptive transfer of T cells engineered with chimeric antigen receptor (CAR) has been proved to have robust anti-tumor effects against hematological malignancies. However, problems about safety and efficacy, such as cytokine release syndrome (CRS), T cell exhaustion and antigen escape are still raised when patients are treated with CAR-T cells. Moreover, CAR-T therapy has limited applications in treating solid tumors, owing to inefficient infiltration and poor functional persistence of CAR-T cells and diverse immunosuppression in tumor microenvironment. In order to overcome these limitations and broad its applications, multiple controllable CAR-T technologies were exploited. In this article, we review the designs of intelligent controlled CAR-T technologies and the innovations that they bring about in recent years.
format Online
Article
Text
id pubmed-10518343
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher KeAi Publishing
record_format MEDLINE/PubMed
spelling pubmed-105183432023-09-26 Intelligent tunable CAR-T cell therapy leads the new trend Cheng, Jiayi Liu, Mingyao Zhang, Jiqin Synth Syst Biotechnol Review Article Adoptive transfer of T cells engineered with chimeric antigen receptor (CAR) has been proved to have robust anti-tumor effects against hematological malignancies. However, problems about safety and efficacy, such as cytokine release syndrome (CRS), T cell exhaustion and antigen escape are still raised when patients are treated with CAR-T cells. Moreover, CAR-T therapy has limited applications in treating solid tumors, owing to inefficient infiltration and poor functional persistence of CAR-T cells and diverse immunosuppression in tumor microenvironment. In order to overcome these limitations and broad its applications, multiple controllable CAR-T technologies were exploited. In this article, we review the designs of intelligent controlled CAR-T technologies and the innovations that they bring about in recent years. KeAi Publishing 2023-09-14 /pmc/articles/PMC10518343/ /pubmed/37753197 http://dx.doi.org/10.1016/j.synbio.2023.09.001 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Review Article
Cheng, Jiayi
Liu, Mingyao
Zhang, Jiqin
Intelligent tunable CAR-T cell therapy leads the new trend
title Intelligent tunable CAR-T cell therapy leads the new trend
title_full Intelligent tunable CAR-T cell therapy leads the new trend
title_fullStr Intelligent tunable CAR-T cell therapy leads the new trend
title_full_unstemmed Intelligent tunable CAR-T cell therapy leads the new trend
title_short Intelligent tunable CAR-T cell therapy leads the new trend
title_sort intelligent tunable car-t cell therapy leads the new trend
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518343/
https://www.ncbi.nlm.nih.gov/pubmed/37753197
http://dx.doi.org/10.1016/j.synbio.2023.09.001
work_keys_str_mv AT chengjiayi intelligenttunablecartcelltherapyleadsthenewtrend
AT liumingyao intelligenttunablecartcelltherapyleadsthenewtrend
AT zhangjiqin intelligenttunablecartcelltherapyleadsthenewtrend